Anti-angiogenic agents like pazopanib have been shown to modulate the tumor immune microenvironment by normalizing vasculature, reducing immunosuppressive cells such as Tregs and MDSCs, and enhancing CD8+ T-cell infiltration in several cancer types. Here, CD8A is linked to neoplasm.